Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

173 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer.
Meylan M, Petitprez F, Becht E, Bougoüin A, Pupier G, Calvez A, Giglioli I, Verkarre V, Lacroix G, Verneau J, Sun CM, Laurent-Puig P, Vano YA, Elaïdi R, Méjean A, Sanchez-Salas R, Barret E, Cathelineau X, Oudard S, Reynaud CA, de Reyniès A, Sautès-Fridman C, Fridman WH. Meylan M, et al. Among authors: verkarre v. Immunity. 2022 Mar 8;55(3):527-541.e5. doi: 10.1016/j.immuni.2022.02.001. Epub 2022 Feb 28. Immunity. 2022. PMID: 35231421 Free article.
A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients.
Adotevi O, Pere H, Ravel P, Haicheur N, Badoual C, Merillon N, Medioni J, Peyrard S, Roncelin S, Verkarre V, Mejean A, Fridman WH, Oudard S, Tartour E. Adotevi O, et al. Among authors: verkarre v. J Immunother. 2010 Nov-Dec;33(9):991-8. doi: 10.1097/CJI.0b013e3181f4c208. J Immunother. 2010. PMID: 20948437 Clinical Trial.
VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis.
Beuselinck B, Karadimou A, Lambrechts D, Claes B, Wolter P, Couchy G, Berkers J, van Poppel H, Paridaens R, Schöffski P, Méjean A, Verkarre V, Lerut E, Joly F, Lebret T, Gravis G, Deplanque G, Descazeaud A, Leclercq NR, Molinié V, Patard JJ, Teghom C, Elaidi R, Zucman-Rossi J, Oudard S. Beuselinck B, et al. Among authors: verkarre v. Acta Oncol. 2014 Jan;53(1):103-12. doi: 10.3109/0284186X.2013.770600. Epub 2013 Feb 20. Acta Oncol. 2014. PMID: 23421954
Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib.
Beuselinck B, Karadimou A, Lambrechts D, Claes B, Wolter P, Couchy G, Berkers J, Paridaens R, Schöffski P, Méjean A, Verkarre V, Lerut E, de la Taille A, Tourani JM, Bigot P, Linassier C, Négrier S, Berger J, Patard JJ, Zucman-Rossi J, Oudard S. Beuselinck B, et al. Among authors: verkarre v. Br J Cancer. 2013 Mar 5;108(4):887-900. doi: 10.1038/bjc.2012.548. Br J Cancer. 2013. PMID: 23462807 Free PMC article.
Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin.
Remark R, Alifano M, Cremer I, Lupo A, Dieu-Nosjean MC, Riquet M, Crozet L, Ouakrim H, Goc J, Cazes A, Fléjou JF, Gibault L, Verkarre V, Régnard JF, Pagès ON, Oudard S, Mlecnik B, Sautès-Fridman C, Fridman WH, Damotte D. Remark R, et al. Among authors: verkarre v. Clin Cancer Res. 2013 Aug 1;19(15):4079-91. doi: 10.1158/1078-0432.CCR-12-3847. Epub 2013 Jun 19. Clin Cancer Res. 2013. PMID: 23785047
Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.
Beuselinck B, Job S, Becht E, Karadimou A, Verkarre V, Couchy G, Giraldo N, Rioux-Leclercq N, Molinié V, Sibony M, Elaidi R, Teghom C, Patard JJ, Méjean A, Fridman WH, Sautès-Fridman C, de Reyniès A, Oudard S, Zucman-Rossi J. Beuselinck B, et al. Among authors: verkarre v. Clin Cancer Res. 2015 Mar 15;21(6):1329-39. doi: 10.1158/1078-0432.CCR-14-1128. Epub 2015 Jan 12. Clin Cancer Res. 2015. PMID: 25583177 Free article.
173 results